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ABSTRACT 
 
Safety concerns are a barrier to prescribing benzodiazepines (BDZ) and opioids in Interstitial 
Lung Disease (ILD). We therefore examined association of BDZ and opioids on risk of 
admission to hospital and death.  
 
We conducted a population based longitudinal cohort study of fibrotic ILD patients starting 
Long Term Oxygen Therapy in Sweden 2005-2014. Effects of BDZ and opioids on rates of 
admission to hospital and mortality were analysed using Fine-Gray and Cox regression whilst 
adjusting for potential confounders.  
 
We included 1,603 patients (61% women). BDZ were used by 196 (12%), opioids by 254 
(15%). There was no association between BDZ and increased admission. Treatment with 
higher vs lower dose BDZ was associated with increased mortality: (SHR 1·46, 95% CI 1·08 
to 1·98) vs (SHR 1·13, 95% CI 0·92 to 1·38). Opioids showed no association with increased 
admission. Neither low dose opioids (<30mg/day morphine equivalent) (SHR 1·18 (95% CI 
0.96 to 1·45) nor high dose opioids (>30mg/day morphine equivalent) (SHR 1·11 (95% CI 
0·89 to 1·39) showed association with increased mortality.  
  
This first ever study to examine associations between BDZ and opioid use and harm in ILD 
supports the use of opioids and low dose BDZ in severely ill patients with respiratory 
compromise.  
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Introduction 
Interstitial Lung Disease (ILD)  is the 40th most frequent cause of death [1] globally with a 
52% increase in mortality in the last ten years.[1] Chronic breathlessness is experienced by 
almost all patients with advanced fibrotic ILD [2-5] and is one of the most common, 
burdensome and neglected symptoms affecting patients representing a major clinical 
management challenge. It has a devastating impact on patients’ lives, severely limiting their 
well-being and quality of life, and that of their family, friends and caregivers. It results in 
high health, social and informal care costs, and is one of the most frequent causes of 
emergency hospital admission and attendance.[6] The recent UK National Institute Clinical 
Excellence guidelines recommend the use of BDZ and/or opioids for symptomatic 
management of breathlessness in idiopathic pulmonary fibrosis (IPF).[7] However, recent 
prospective studies showed that BDZ [8] and higher dose opioids [8, 9] were associated with 
increased hospital admissions and deaths in patients with COPD. In contrast, lower dose 
opioids (≤30 mg oral morphine equivalents/day), were not associated with hospitalization or 
mortality in this group.[8]  
 
Data on the safety of BDZ and opioids in ILD are poor with only one relevant study [10] 
where treatment outcome of 22 patients with severe interstitial pneumonia who received 
opioids for 24 hours during end-of-life care were retrospectively examined. Twenty-two 
consecutive patients were retrospectively evaluated before and after continuous 
administration of opioids for 24 hours. All subjects died within 21 days; the mean survival 
period after opioid administration was 5·6 days. Six of the 22 patients (27%) died within 24 
hours after opioids were initiated and hypercapnia was noted. 
Ongoing concerns that these medications may cause adverse events, including respiratory 
depression, confusion, falls, and even premature death are cited as barriers for respiratory and 
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palliative care health professionals.[3] These concerns may cause reluctance to prescribe and 
use these medications, thus contributing to less than optimal symptomatic management with 
unnecessary suffering and hospital admissions. Data on safety may help inform day to day 
management and guide clinicians on optimal management of disabling symptoms.  
 
We therefore estimated the association of BDZ and opioids on the risk of admission to 
hospital and death in patients with respiratory failure attributable to fibrotic ILD.  
 
 
Material and methods 
STUDY SUBJECTS 
We included physician diagnosed pulmonary fibrosis patients aged 45 years or older starting 
LTOT between October 1, 2005 and December 31, 2014 (time period with available data on 
medications). Causes of pulmonary fibrosis included (but were not limited to) IPF, non-
specific interstitial pneumonia. We excluded patients that had received lung transplantation. 
For patients who started LTOT more than once (n=24), only the most recent treatment 
episode was included in the analysis. Data were collected in Swedevox at baseline (start of 
LTOT); forced expiratory volume in one second (FEV1) % of predicted, vital capacity (VC) 
% of predicted, FEV 1/VC, arterial blood gas tension of oxygen (PaO2) and carbon dioxide 
(PaCO2) whilst breathing air and oxygen, smoking status, body mass index (BMI) and World 
Health Organisation (WHO) performance status.  
The study was approved by the Lund University research ethics committee (Dnr: 2016/846), 
the Swedish National Board of Health and Welfare, and the Data Inspection Board. 
Individual patient consent was not required as the study used de-identified and un-re-
identifiable data aggregated nationally.  
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STUDY DESIGN 
This was a nationwide, prospective, population-based study of patients with physician 
diagnosed oxygen-dependent fibrotic ILD in the Swedish National Registry of Respiratory 
Failure (Swedevox).[11] Swedevox covers approximately 85% of patients starting long-term 
oxygen therapy (LTOT) nationwide since 1987.[11] 
 
METHODS 
We obtained data on co-morbidities and hospital admissions from the National Patient 
Register for inpatient and outpatient care for four years before baseline (complete data on 
hospitalisations since 1987 and on specialised outpatient care since 2001).[12] Data on all 
dispensed prescriptions during outpatient care after July 1 2005 were obtained from the 
Swedish Prescribed Drug Register. The medications of interest were categorised according to 
the Anatomical Therapeutic Chemical Classification System (ATC codes) as benzodiazepines 
(N05BA), weak opioids (N02AA59, N02AX02), strong opioids (N02A except weak), oral 
corticosteroids (H02A), azathioprine (L04AX01) and n-acetylcysteine (R05CB01). 
 
ANALYSIS 
Medication exposure was defined as at least one dispensed prescription during the 91 days 
before baseline. Exposure during follow-up was tabulated for patients classified as unexposed 
and exposed at baseline to evaluate whether baseline exposure was a good proxy for 
subsequent use during follow-up. Exposure to BDZ and opioids were coded dichotomously 
(treated vs. non-treated), continuously as the baseline dose, and categorised into lower and 
higher dose treatment. The baseline dose was calculated as the mean dispensed WHO defined 
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daily doses (DDDs) per day during the 91 days before baseline. Lower dose treatment was 
defined as ≤0.3 DDD/day corresponding to ≤30 mg oral morphine equivalents/day, as this is 
the current evidence based dose range for opioid treatment for chronic breathlessness. [13, 
14]. The same cut off was used for BDZ as it corresponded to the median dose in the 
exposed. Lower dose treatment defined as <0.3 DDD/day corresponded to <15mg oral 
oxazepam equivalents/day. 
BDZ (453 dispensed prescriptions) included oxazepam (87%), diazepam (6%) and 
alprazolam (5%). Opioids included the weak opioids (281 dispensed prescriptions) tramadol 
(53%), codeine (47%), and the strong opioids (351 dispensed prescriptions) oxycodone 
(49%), morphine (25%), fentanyl (9%) and dextropropoxyphene (9%). 
Missing data were imputed for BMI (n=380), FEV1 (n=623), VC absolute value (n=628) and 
percentage predicted (n=685), PaO2 on room air (n=359), PaCO2 on oxygen (n=366) and 
PaCO2 on oxygen (n=249) using chained multiple imputation.[15] Outcome variables (days 
to death and days to hospitalisation) and covariates from the final models were used to 
estimate missing values. Number of imputations was set to 30 to reflect the amount of 
missing data [15] and imputed values were incorporated in the final models using Rubin’s 
rules.[15] Covariates to be included in the final models were selected using subject matter 
knowledge.[8] Sensitivity analyses were conducted in people with complete data on all 
variables in the final models  (complete case analysis) and excluding concurrent users of 
BDZ and opioids (n=59; 4%); see appendix A).  
Associations with the rates of hospitalisation were expressed as sub-distribution hazard ratios 
(SHRs) estimated using Fine-Gray regression, which accounts for the competing risk of 
death.[16] For hospitalisations, the time under observation was from the first non-hospitalised 
day during LTOT until the date of first hospitalisation from all causes, with censoring at 
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withdrawal of LTOT, death, or study end (December 31, 2014). Associations with mortality 
were expressed as hazard ratios (HRs) and estimated using Cox regression. For mortality, the 
observation time was from the date of starting LTOT until the date of death from all causes, 
with censoring at withdrawal of long-term oxygen therapy, or study end. The assumption of 
proportional hazards for the medication effects was assured using Kaplan Meier plots and by 
splitting follow-up time to examine time-specific effects. We calculated 95% confidence 
intervals (CI) for all estimates. Statistical analyses were performed with Stata SE v13.[17] All 
data have been reported in line with STROBE guidance.[18]  
 
RESULTS 
In this population based longitudinal cohort study, there was no loss to follow-up. We 
included 1,603 patients (61% women) with fibrotic ILD starting LTOT. In the preceding 4 
years there was a rheumatologic diagnosis (any) in 7.3%, pneumoconiosis in 3%, sarcoidosis 
in 1.7% and hypersensitivity pneumonitis was present in 1.5%. As shown in Table 1, BDZ 
were used by 196 (12%) patients, opioids by 252 (16%), and 59 (4%) patients were using 
both BDZ and opioids. Compared with non-users, patients taking BDZ or opioids were more 
likely to be female, have a lower FEV1% of predicted, worse performance status, more 
hospitalisations in the 91 days prior to baseline and more comorbidities. Of note, there was 
no difference in their baseline lung function. Exposure to BDZ and opioids throughout 
follow-up was higher among patients with baseline exposure, and patients unexposed at 
baseline had low rates of exposed time during subsequent follow up (Table 2) 
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Table 1 Baseline characteristics according to treatment status of 1,603 patients with oxygen 
dependent fibrotic ILD.  
 Benzodiazepi
ne (n=196) 
Opioid 
(n=252) 
Unexposed 
(n=1,214) 
P value  
Age at starting LTOT, years 77.5 (8.2)  76.1 (8.9) 76.3 (8.8) 0.156 
Women, n (%) 89 (45.4) 123 (48.8) 415 (34.2) <0.001 
FEV1 % of predicted* 66.3 (37.3) 67.0 (39.7) 71.6 (40.3) 0.106 
VC % of predicted* 54.7 (34.2) 56.2 (35.6) 60.4 (34.7) 0.052 
FEV1/VC* 0.9 (0.3) 0.9 (0.3) 0.8 (0.4) 0.427 
PaO2 breathing air*, kPa 6.5 (1.0) 6.6 (1.0) 6.6 (1.0) 0.441 
PaCO2 breathing air*, kPa 5.3 (1.0) 5.3 (1.0) 5.1 (0.9) <0.001 
PaO2 breathing oxygen*, kPa 5.7 (0.9) 5.7 (1.0) 5.4 (1.0) 0.001 
Smoking status, n (%) 
Never 
Former 
Former/current 
Missing 
 
61 (31.1) 
1 (1.0) 
105 (53.6) 
30 (15.31) 
 
66 (26.2) 
3(1.2) 
149 (59.1) 
37 (14.7) 
 
338 (27.8) 
9(0.7) 
698 (57.5) 
178 (14.7) 
 
0.797 
Body mass index (BMI)**, kg/m2 
<18.5 
18.5-24.9 
25-29.9 
≥30 
 
10 (5.1) 
107 (54.6) 
53 (27.0) 
26 (13.3) 
 
12 (4.8) 
143 (56.8) 
67 (26.6) 
30 (11.9) 
 
35 (2.9) 
707 (58.2) 
314 (25.9) 
158 (13.0) 
 
0.579 
No (%) WHO performance status 
0-1 
2 
3-4 
Missing 
 
76 (38.8) 
54 (27.6) 
49 (25.0) 
17 (8.7) 
 
93 (36.9) 
70 (27.8) 
60 (23.8) 
29 (11.5) 
 
566 (46.6) 
350 (28.8) 
161 (13.3) 
137 (11.3) 
 
<0.001 
Median  (IQ) number of 
hospitalisations within four years 
before baseline 
4 (2-6) 4 (2-6) 2 (1-4) <0.001 
Median (IQ) number of hospitalised 
days out of the 91 days before 
baseline 
14 (5.5 – 24) 15 (8 – 27) 11.5 (4 - 21) <0.001 
Percent of follow up time 
hospitalised (follow up time/ 
hospitalised days) 
7.6 (2.3-20.3) 8.4 (2.6-
19.8) 
6.2 (2.1-
16.8) 
0;175 
No (%) Cardiovascular diseases   
0 
1 
2 
≥3 
 
45 (23.0) 
3 (1.5) 
65 (33.2) 
83 (42.4) 
 
59 (23.4) 
3 (1.2) 
68 (27.0) 
122 (48.4) 
 
416 (34.3) 
58 (4.8) 
300 (24.7) 
440 (36.2) 
 
<0.001 
Comorbidity, n (%) 
COPD 
Cancer 
Depression/anxiety  
Diabetes mellitus  
Injury  
Osteoporosis  
Renal failure  
Pulmonary hypertension  
 
50 (25.5) 
81 (41.3) 
43 (21.9) 
44 (22.5) 
33 (16.8) 
11 (5.6) 
18 (9.2) 
12 (6.1) 
 
67 (26.4) 
107 (42.5) 
33 (13.1) 
73 (29.0) 
54 (21.4) 
35 (13.9) 
25 (9.9) 
24 (9.5) 
 
234 (19.3) 
417 (34.4) 
37 (3.1) 
219 (18.0) 
154 (12.7) 
47 (3.9) 
65 (5.4) 
86 (7.1) 
 
0.010 
0.016 
<0.001 
<0.001 
<0.001 
<0.001 
0.007 
0.315 
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GERD  12 (6.1) 18 (7.1) 37 (3.1) 0.003 
Benzodiazepine, n (%) 
Higher (>15mg oral oxazepam 
equiv/day) 
Low (< 15mg oral oxazepam 
equiv/day) 
 
65 (33.2) 
 
131 (66.8) 
 
27 (10.7) 
 
32 (12.7) 
 
- 
- 
 
Opioid, n (%) 
Higher (>30mg oral morphine 
equiv/day) 
Low (≤30 mg oral morphine 
equiv/day)  
 
33 (16.8) 
 
27 (13.8) 
 
122 (48.4) 
 
130 (51.6) 
 
- 
 
- 
 
Oral corticosteroids, n (%) 107 (54.6) 135 (53.6) 603 (49.7) 0.284 
Azathioprine, n (%) 8 (4.1) 13 (5.2) 89 (7.3) 0.142 
N-Acetylcysteine, n (%) 81 (41.3) 76 (30.2) 372 (30.6) 0.010 
Data presented as means (standard deviation) unless otherwise stated. P value calculated using anova, kwallis or 
X2 
*summary statistics for imputed data applying Rubin’s combination rules, % missing: FEV1 % of predicted 
(42.4%); VC % of predicted (42.7%); FEV1 (38.9%); VC (39.2%); PaO2 breathing air (22.4%); PaCO2 
breathing air (22.8%); PaO2 breathing oxygen (15.5%). Immunosupressive drugs (including mycophenolate) 
used by 5 patients at baseline.  
**Missing BMI (31.1%) imputed into category 18.5-24.9 
 
 
 
Table 2 Exposure to benzodiazepines and opioids in 1,603 patients with fibrotic ILD.  
 Benzodiazepines Opioids 
Exposed at baseline 
Total 
Low dose 
Higher dose 
Median (IQR) dose at baseline (DDD/day) 
Exposed at baseline but unexposed during follow-up 
Median (IQR) exposure during follow-up (% of time) 
Medication-naïve (unexposed) in preceding 12 months* 
 
196 
131 (66.8) 
65 (33.2) 
0.2 (0.1-0.4) 
51 (26.0) 
83 (0-100) 
55 (29.3) 
 
252 
130 (51.6) 
122 (48.4) 
0.3 (0.1-0.5) 
77 (30.6) 
63 (0-100) 
59 (25.0) 
Not exposed at baseline 
Total 
Unexposed at baseline but exposed during follow-up 
Median (IQR) dose during follow up (DDD/day) 
Median (IQR) exposure during follow-up (% of time) 
Medication-naïve (unexposed) in preceding 12 months* 
 
1,407 
429 (30.5) 
0.0 (0.0-0.0) 
0 (0-16) 
1,199 (92.7) 
 
1,351 
401 (29.7) 
0.0 (0.0-0.0) 
0 (0-10) 
1,034 (83.1) 
*Among patients with at least 12 months medication exposure data (n=1,481). Figures are numbers 
(percentages) unless stated otherwise 
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Admission to hospital 
Overall, treatment with BDZ had no significant association with increased rates of 
hospitalisation, SHR 1.21 (95% CI 1.00 to 1.46). Further analysis of low dose BDZ (<0.3 
DDD/day; SHR 1.19, 95% CI 0.95 to 1.49) and high dose BDZ (>0.3 DDD/day; SHR 1.27, 
95% CI 0.92 to 1.73) showed no association with hospitalisation. Opioids were not associated 
with hospitalisation, SHR 1.14, 95% CI 0.96 to 1.35. Low dose opioids (<0.3 DDD /day; 
SHR 1.21, 95% CI 0.96 to 1.52) and higher dose opioid treatment (>0.3 DDD /day; SHR 
1.08, 95% CI 0.86 to 1.35) did not increase the rate of admission. There were no dose-
response relations (Table 3 and Figure 1). 
Mortality 
In general, opioids were associated with increased mortality, SHR 1.18 (95% CI 1.01 to 
1.38). However, a detailed analysis of the adjusted risks for each dose level showed that 
neither low dose opioids (SHR 1.22; 95% CI 0.99 to 1.50) nor higher dose opioids (SHR 
1.11; 95% CI 0.89 to 1.39) were associated with increased mortality. BDZ treatment was 
related to mortality (HR 1.21; 95% CI 1.01 to 1.44) and this was dose dependent. Low dose 
BDZ was not associated with mortality (SHR 1.13, 95% CI 0.92 to 1.38) whereas higher dose 
BDZ was associated with increased mortality (SHR 1.46, 95% CI 1.08 to 1.97; (Figure 2 and 
3). As a further predictor, a WHO performance status of 3 or 4 was associated with increased 
mortality (SHR 2.00; 95% CI 1.67 to 2.38).  
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Table 3 Benzodiazepine and opioids and adjusted hazard ratio of admission to hospital 
and mortality in 1603 patients with LTOT dependent fibrotic ILD.  
 Adjusted hazard ratio (95%CI)* 
 Admission Mortality 
Benzodiazepines:   
 Untreated 1 1 
 Low dose 1.19 (0.95 to1.49) 1.13 (0.92 to 1.38) 
 Higher dose 1.27 (0.92 to 1.73) 1.46 (1.08 to 1.97) 
Opioids:   
 Untreated 1 1 
 Low dose 1.21 (0.96 to 1.52) 1.22 (0.99 to 1.50) 
 Higher dose 1.08 (0.86 to 1.35) 1.11 (0.89 to 1.39) 
Covariates   
Age (years) 0.98 (0.98 to 0.99) 1.02 (1.01 to 1.03) 
Male 1.05 (0.93 to 1.19) 1.41 (1.24 to 1.60) 
VC % of predicted 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 
FEV1/VC 1.07 (0.94 to 1.22) 0.99 (0.89 to 1.11) 
PaO2 breathing air 1.00 (0.93 to 1.07) 1.00 (0.94 to 1.07) 
PaCO2 breathing air 0.95 (0.84 to 1.07) 0.89 (0.79 to 1.00) 
PaO2 breathing oxygen 0.99 (0.88 to 1.10) 0.99 (0.89 to 1.11) 
BMI 
 <18.5 
 18.5-24.9 
 25-29.9 
 ≥30 
 
1 
1.26 (0.86 to 1.85) 
1.30 (0.87 to 1.92) 
1.28 (0.85 to 1.93) 
 
1 
0.72 (0.52 to 0.99) 
0.70 (0.50 to 0.97) 
0.54 (0.38 to 0.77) 
WHO performance status 
 0-1 
 2 
 3-4 
 Missing 
 
1 
1.09 (0.95 to 1.25) 
0.78 (0.63 to 0.96) 
1.04 (0.86 to 1.26) 
 
1 
1.48 (1.29 to 1.70) 
2.00 (1.67 to 2.38) 
1.49 (1.22 to 1.81) 
N of cardiovascular diseases 
 0 
 1 
 2 
 ≥3 
 
1 
1.11 (0.85 to 1.47) 
1.05 (0.90 to 1.22) 
1.04 (0.89 to 1.21) 
 
1 
1.03 (0.76 to 1.41) 
0.99 (0.85 to 1.16) 
1.05 (0.90 to 1.23) 
Comorbidity 
 Cancer 
 Depression/anxiety  
 Diabetes mellitus  
 Injury  
 Osteoporosis  
 Renal failure  
 Pulmonary hypertension  
 GERD  
 
1.15 (1.02 to 1.30) 
0.79 (0.60 to 1.05) 
0.95 (0.82 to 1.10) 
1.05 (0.90 to 1.24) 
1.03 (0.80 to 1.33) 
0.83 (0.61 to 1.13) 
0.88 (0.68 to 1.14) 
1.15 (0.85 to 1.56) 
 
0.85 (0.75 to 0.96) 
1.08 (0.82 to 1.41) 
1.04 (0.90 to 1.20) 
1.10 (0.93 to 1.29) 
0.83 (0.64 to 1.09) 
1.50 (1.19 to 1.90) 
1.10 (0.86 to 1.41) 
0.85 (0.62 to 1.17) 
N hospitalisations within 4 years before baseline 1.05 (1.02 to 1.07) 0.99 (0.97 to 1.01) 
N hospitalised days within the 91 days before baseline 1.00 (1.00 to 1.01) 1.00 (1.00 to 1.01) 
*Model adjusted for all variables in the table as well as smoking status, and use of corticosteroids, azathioprine 
and NAC
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Figure 1 Forest plot of BDZ and opioids and admissions 
Figure 2 Forest plot of BDZ and opioids and mortality 
Figure 3 CIF plot of BDZ on mortality 
 
Sensitivity Analyses 
A complete case analysis was carried out for comparison and is shown in Appendix A. 
Observed differences between the models are minor, however, in the complete case analysis, 
higher dose BDZ are no longer a significant predictor of mortality and higher dose opioids 
become a significant predictor of admissions. Given the much smaller sample in the complete 
case analysis, and the bias introduced by excluding those cases with missing data, the models 
presented in table 3 using imputed data are more robust.  When removing concurrent users of 
both BDZ and opioids, findings were similar as to in the main analysis (Appendix A). 
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Discussion 
In this nationwide, population-based study using prospectively collected, linked, routine 
clinical data, the main findings are that treatment with opioids were not associated with 
increased risk of admission to hospital or death in patients with oxygen-dependent fibrotic 
ILD. Treatment with BDZ was not clearly associated with the rate of hospital admission but 
was associated with increased mortality at higher doses.  
Internationally, no medication is licensed for chronic breathlessness, but emerging evidence 
in other disease groups such as COPD supports regular, low dose morphine as safe and 
efficacious. This is the first study examining safety data for BDZ  or opioids in ILD.  
Ekström et al [8] studied 2,249 patients with oxygen-dependent COPD in Swedevox and 
found that lower dose opioids were not associated with increased admissions or deaths. 
However, higher doses of opioids and all doses of BDZ were associated with increased 
admissions and increased mortality.  This is in contrast to Vozoris et al [9] who also 
conducted a registry-based study and found that people with COPD prescribed opioids who 
had an incident opioid prescription had a 30-day mortality risk of 1.9% compared with 1.1% 
without an opioid prescription after propensity score matching; an absolute difference of 
0.8%. However, it was not clear that the observed risk difference was due to opioid 
medication as there were many potential confounders.[19] In contrast, our study does not 
show an association between opioids at either low or high dose and harm.  
BDZ reduce the sensation of breathlessness through decreasing the anxiety associated with 
breathlessness.[20] Our data shows that depressed/anxious patients were much more likely to 
be prescribed BDZs and opioids. Ekstrom et al found that all doses of BDZ were associated 
with increased admissions and increased mortality in their COPD patients.  Our study also 
does not clearly show an association between BDZ use and hospital admission but does 
suggest an association with mortality. As our patient group included palliative care patients, a 
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possible explanation, at least partly, for this is that there was increased BDZ use at the end of 
life for management of anxiety-related breathlessness as recommended by clinical 
guidance.[20] Supporting this, worse performance status was also associated with increased 
mortality.  
 
Our data show that the use of BDZ and opioids in fibrotic ILD was low (12% and 15% 
respectively) and that opioid prescribing is much lower than that found in a retrospective 
review of fibrotic ILD patients in the last year of life in the UK (18% and 49% 
respectively).[2] In addition, our medication-naïve group (Table 2) was much larger than that 
found by Ekstrom et al.[8] This suggests that BDZ and opioids when used, are not being used 
until disease is advanced and patients are oxygen dependent. This is despite universal 
breathlessness at presentation.[5, 21] This is potentially a group of patients that may benefit 
from holistic management of symptomatic chronic breathlessness (which is not focussed on 
oxygen saturations) including the use of BDZ and opioids earlier in the disease process.  
 
A recent ILD position statement stressed the importance of delivering early and effective 
palliative care.[22] This study provides novel data on the safety of BDZ and opioids in 
oxygen dependent ILD and may allay fears of clinicians who have been reluctant to prescribe 
these medications. Higginson et al [23] linked 14 years of death registration data and showed 
that 45,712 people died of ILD in England between 2001-2014 with increases of 9.2% 
annually. Importantly, 70% of these deaths were in hospital.  Improvements in breathlessness 
management may decrease patient admissions and deaths and improve the quality of life of 
ILD patients and carers.  
 
15 
 
Patients with Interstitial Lung Disease have a wide range of diagnoses and prognoses. Many 
patients can live many years with their diagnosis and some are responsive to treatments. 
However, a subset of patients with progressive fibrotic ILD such as IPF have a short disease 
trajectory and a similar prognosis to people with lung cancer.[24] It is important to 
differentiate fibrotic disease in the early stages when the disease is potentially responsive to 
therapy.[25] However, when the disease is advanced and irreversible, this becomes less 
important and the focus should be on symptom control. 
IPF is one of the most common ILDs. Recent European data reflects worldwide data that IPF 
is more common in males (approx. 60:40) and this prevalence increases with age.[26, 27] Our 
data at baseline reflect a higher proportion of women (61%). On analysis, there were a higher 
proportion of men in the unexposed group compared with the exposed group, indicating that 
women with fibrotic ILD are more likely to be prescribed BDZ and opioids. In COPD, the 
physiologic changes affect women and men differently in terms of symptoms and quality of 
life. For a similar degree of physiologic impairment, women experience more severe 
breathlessness and worse health status.[28] Women with COPD also demonstrate higher 
levels of anxiety and depression and worse symptom-related quality of life than their male 
counterparts.[29] Comparable data in ILD are lacking and warrant further investigation to 
enable symptom management to be tailored to individual needs.  
 
Strengths and limitations of the study 
The present findings pertain to patients with severe oxygen dependent fibrotic ILD. This is a 
strength of the study as this population with advanced disease and respiratory compromise 
may be more likely to experience adverse events. Thus, the absence of a clear association for 
opioid use and low dose BDZ with hospitalisations and mortality is most informative in this 
population. As only 60 patients had concurrent BDZ and opioid use, we were unable to 
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analyse the association of concurrent medications and we were also unable to examine the 
effect of short-acting vs long-acting drug forms. This was a convenience cohort, not 
necessarily powered to answer a question on safety and we did not have an a priori power 
calculation.  Therefore, we cannot exclude an effect that may be clinically significant. 
However, a lack of association of harm is informative. These data are comprehensive but 
limited to Sweden. Data on diagnostic procedures were unavailable therefore we are unable 
to present individual fibrotic ILD diagnoses. However, in a previous validation of fibrotic 
ILD diagnoses in the Swedevox register which included review of medical records, 80% were 
classified as probable IPF.[30] Similar selection criteria were used in the present study. 
Recent development of IPF registries worldwide [31, 32] have enabled the documentation of 
important parameters including type of ILD, lung function, radiology, quality of life, ongoing 
treatments, follow-up and outcomes such as death and lung transplantation. This will make 
analyses of worldwide data related to ILD easier going forward. This study highlights that 
registry data needs to be complemented with detailed pharmacovigilance randomized 
controlled trials quantifying adverse events and benefits to further direct clinical care. 
This is the first ever study to examine associations between BDZ and opioid use and harm in 
ILD patients. The evidence generated indicates that opioids are not associated with harm in 
people with severe oxygen-dependent ILD. Higher dose BDZ may be associated with 
increased mortality. The possibility of true causal effects, however, needs to be validated by 
randomised controlled trials.  
By providing valuable data on the safety of BDZ and opioids, this study may allay fears of 
clinicians who have been reluctant to prescribe these medications. This study supports the use 
of opioids and low dose BDZ to manage breathlessness in severely ill ILD patients with 
respiratory compromise- patients who have significant symptom burden which impacts every 
17 
 
part of patients’ and carers’ lives. Increased prescribing may lead to improved symptom 
control and quality of life for this patient group.  
18 
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